Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Trabectedin in Solid Tumors
NCT03496519Phase 1Withdrawn
- Sponsor
- University of Colorado Denver
- Start
- Oct 2018
- Primary completion
- Oct 2021
- Modality
- Antibody Conjugates, Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules
01
Overview
Phase 1, open-label trial of durvalumab and trabectedin in solid tumor, non-small cell lung cancer (NSCLC) and sarcoma (2 arms), sponsored by University of Colorado Denver. Primary endpoints: Recommended Dosage of the Durvalumab and Trabectedin Combination at 15 months and Maximum Tolerated Dose at 42 days. Planned start Oct 2018; status: withdrawn.
02
Drugs
durvalumabtrabectedin
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)sarcoma
Beyond the preview
Go deeper on NCT03496519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03496519.